allo-HSCT. [6] [7] [8] In these situations, efficacy remains limited with overall survival (OS) ranging from 20-30%. We and others previously reported that OS may be improved (to 50-80%), when DLI is performed in a preemptive manner, guided by chimerism and/or molecular residual disease results.
9-11 Thus, we hypothesized that the use of prophylactic DLI (pDLI) may be considered as an interesting way to prevent AML recurrence. However, the anticipated risk of pDLI-induced GvHD may counterbalance its potential benefit. To date, few experiences of pDLI for AML are available, making that both efficacy and safety remain unclear.
Thus, we report here the outcome of AML patients transplanted at the Paoli-Calmettes Institute and who received pDLI. We started the use of pDLI in patients transplanted for refractory AML and progressively proposed this strategy also in CR patients with high risk of relapse, based on cytogenetic and/or molecular disease characteristics. In our experience, 22 patients with high-risk AML received pDLI from 2006 to 2015 (details in Table 1 ). AML patients were at high risk because of refractory disease at the time of allo-HSCT (n = 10), relapse AML (n = 4, 2 after a first allo-HSCT), CR1 AML with unfavorable cytogenetics (n = 6), CR1 AML with high FLT3-internal tandem duplication/FLT3-wild type ratio at 0.75 (n = 1) or CR1 AML with numerous induction chemotherapy courses needed to obtain CR (n = 1). All patients received a fludarabine/busulfan-based conditioning regimen, with reduced (2 days at 130 mg/m 2 per day) or myeloablative doses (3 or 4 days at 130 mg/m 2 per day) of IV busulfan. Patients who underwent allo-HSCT from haploidentical donor were given additional thiotepa in the conditioning regimen and post-transplantation cyclophosphamide. Eight of the 10 patients with refractory AML at the time of allo-HSCT received the RIC regimen during the aplasia, following a debulking intensive chemotherapy course as a so-called sequential approach. pDLI was performed in a median time of 130 days post allo-HSCT (range: 85-242). At the time of pDLI, all patients were in CR with a T-cell donor chimerism of at least 90%, and 13 (59%) were still receiving immunosuppressive treatment (IST). The CD3+ cell doses of the first pDLI ranged from 0.1 to 10x10 6 CD3-positive cells per kg. Nine patients received First pDLI under IST 13 59
Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation; Bu = IV busulfan; Flu = fludarabine; IST = immunosuppressive treatment; MAC = myeloablative conditioning; pDLI = prophylactic donor lymphocyte infusion; RIC = reduced intensity conditioning. more than one pDLI (two pDLI, n = 7; three pDLI, n = 2), with increased CD3-positive cell doses. The cumulative incidence of GvHD after pDLI was 37% (95% confidence interval (CI): 13-54). Clinical features of GvHD were chronic in six patients (one mild, four moderate and three severe according to the National Institutes of Health classification) and two presented with overlap syndrome. GvHD occurred after one (n = 4), two (n = 3) and three (n = 1) pDLI, in a median time of 37 days (range: 8-99) after the last given pDLI. Seven of these eight patients (88%) were still alive and leukemia free at the last follow-up with a median follow-up of 16 months (range: 6-31) after the first pDLI (6/14 (57%) for patients without GvHD). Among these eight patients, one had no chronic GvHD symptom and no IST, whereas six presented chronic GvHD features at the last follow-up (mild n = 2, moderate/severe n = 4 and still on treatment). The remaining patient who developed GvHD presented AML relapse 32 months after pDLI and died 3 months later. There was no GvHD-related death. We found no difference in the cumulative incidence of GvHD according to the presence of ongoing IST at the time of the pDLI (pDLI with vs without IST: 38 vs 33%, P = 0.689). These results suggest that the incidence of GvHD after pDLI remains comparable to that commonly expected in our overall population after allo-HSCT. 12 It is not clear if the GvHD appearance after pDLI is due to the concomitant tapering of IST and/or to the pDLI itself. Other groups also reported that GvHD is frequent after DLI, but without evidence of increased risk of nonrelapse deaths. 13, 14 The cumulative incidence of relapse at 2 years after pDLI was 25% (95% CI: 3-43; Figure 1 ). AML recurrence occurred at a median time of 4 months (range: 1-88) with only two patients relapsing after 2 years (making the relapse incidence at 5 years of 44% (95% CI: 0-69)). Five of the seven relapsing patients died from relapse. Non-relapse mortality was 0%. Overall, 2-year leukemia-free survival and OS after pDLI were 75% (95% CI: 58-97) and 76% (95% CI: 57-100), respectively ( Figure 1) . Moreover, focusing on the 10 patients who were transplanted for refractory AML, although the incidence of GvHD was high (60%), there was no non-relapse death. Only three patients relapsed leading to death in two cases (2-year OS: 80%). These results are very encouraging taking into account the very poor baseline characteristics of patients. However, they should be considered with caution regarding the efficacy of pDLI, because this study focused on patients who remain leukemia free during a sufficiently long period after allo-HSCT to receive pDLI. A recent study using a multistate model aimed to deal in part with this issue and showed that pDLI was associated with lower risk of AML relapse. 15 Overall, we conclude that: (1) pDLI is feasible, without evidence for increased incidence of GvHD; (2) considering the very high risk of disease and the absence of non-relapse death in our series, we suggest that pDLI may be performed in this setting with encouraging outcome; and (3) the clinical benefit needs to be assessed in a comparative prospective trial.
